Search Within


Applied Filters:
Showing 1-7 of 7 results for "255M-1" within Papers
A Gasbarri et al.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 17(11), 3494-3502 (1999-11-05)
Thyroid cancer is the most frequently occurring endocrine malignancy; however, preoperative diagnosis of some lesions, in particular those with follicular histology, is difficult, and a consistent number of not otherwise-specified "follicular nodules" are surgically resected more for diagnosis than therapeutic
K N Konstantinov et al.
The American journal of pathology, 148(1), 25-30 (1996-01-01)
Galectin-3 is a member of a newly named family of beta-galactoside-binding animal lectins, which has been described with a number of possible important biological functions, including the regulation of cell growth and association with tumor transformation. This protein has a
Marille E Herrmann et al.
Archives of pathology & laboratory medicine, 126(6), 710-713 (2002-05-30)
The expression of galectin-3, a human lectin, has been shown to be highly associated with malignant behavior of thyroid lesions. We studied the immunohistochemical expression pattern of galectin-3 in a variety of follicular-derived thyroid lesions (13 benign and 62 malignant)
F Orlandi et al.
Cancer research, 58(14), 3015-3020 (1998-07-29)
Galectin-3 is a carbohydrate-binding protein endowed with an affinity for beta-galactosides. It has been shown to play an important role in cell-cell and cell-matrix interactions and in pre-mRNA splicing. Furthermore, it is involved in the control of cell growth, neoplastic
Mauro Papotti et al.
European journal of endocrinology, 147(4), 515-521 (2002-10-09)
Cystic thyroid lesions can harbour an occult papillary carcinoma, which fine needle aspiration (FNA) biopsy may fail to detect. Recently, new markers such as galectin-3 lectin have been proposed to distinguish benign from malignant thyroid lesions of follicular origin. The
H Inohara et al.
Cancer, 85(11), 2475-2484 (1999-06-05)
Galectin-3 is a beta-galactoside-binding protein that has been reported to be expressed preferentially in thyroid malignancies. The current study was designed to substantiate this finding further and to establish a presurgical diagnostic modality of differentiating between benign and malignant thyroid
A Bartolazzi et al.
Lancet (London, England), 357(9269), 1644-1650 (2001-06-27)
Thyroid cancer is the most common endocrine malignant disease, but preoperative diagnosis remains a challenge. Fine-needle aspiration cytology has greatly improved the clinical management of thyroid nodules, but the preoperative characterisation of follicular lesions is very difficult. Many patients are
Page 1 of 1